Orthopedics This Week - 2018 | July 17, 2018 | Page 26
ORTHOPEDICS THIS WEEK
VOLUME 14, ISSUE 23 | JULY 17, 2018
He said that one of the biggest take-
aways from the study was that they
identified worsened dual-task gait
costs across a typical clinical recovery
time line among those who went on to
sustain an acute time-loss injury during
the year following their concussion, but
not for those who did not sustain an
additional injury.
He added, “Although preliminary, these
findings indicate that the ability to suc-
cessfully execute a gait and cognitive task
simultaneously may worsen across clinical
recovery among those who go on to sus-
tain a subsequent injury during sports.”
“Tests that incorporate simultaneous task
performance across different domains
may aid in identifying those at risk for
further injury and thus assist clinical
decision making,” he added. — TR
SPINE
Study on PEEK,
Osseointegration and
Fusion
A
ccording to NuVasive, Inc., a study
published April 25, 2018 in the
Journal of Spine & Neurosurgery has
found that the company’s “patented
porous polyetheretherketone (PEEK)
technology is a clinically viable alterna-
tive for improving osseointegration and
fusion rates of interbody implants to
treat degenerative cervical disc disease.”
The study is titled, “Early Outcomes
of Anterior Cervical Discectomy and
Fusion Using Porous PEEK Interbody
Fusion Device.”
A total of 50 patients with degenera-
tive cervical disc disease underwent
anterior cervical discectomy and fusion
(ACDF) using NuVasive’s Cohere cervi-
cal interbody fusion device. The com-
pany indicates that all patients experi-
enced positive results.
“This interbody fusion device with
Porous PEEK surface technology provid-
ed improved osseointegration and sup-
ported spinal fusion in single level and
multi-level cervical fusions,” said study
author Dr. J. Kenneth Burkus of the
Hughston Clinic in Columbus, Georgia.
“Twelve-month clinical outcomes have
demonstrated the efficacy and stability
of the Cohere Porous PEEK interbody
device and shown that it is a clinically
viable implant alternative for achieving
successful clinical and radiological out-
comes in cervical spine fusion surgery,
particularly in multi-level or revision
surgeries where fusion rates are lower.”
According to the company, “During the
course of the clinical study, there were
11 1-level, 23 2-level and 16 3-level
fusions between C3 and C7. Patients
came from all walks of life and with
various comorbidities. Thirteen of them
had previously had an unsuccessful
anterior cervical fusion procedure.”
26
fusion six months after the surgery.
At 12 months post-operative ACDF
surgery, all 50 patients demonstrated
improved motion, decreased neck pain
and average disc height increased by
more than 4 mm. In addition, each of
them showed radiographic fusion.”
Matt Link, executive vice president,
strategy, technology and corporate
development for NuVasive, told OTW,
“The study by Dr. Burkus demonstrat-
ed remarkable results with the Cohere
Porous PEEK device in as little as six
months with improved clinical outcomes
and excellent fusion rates. We look for-
ward to sharing these exciting findings
with our surgeon and hospital custom-
ers. The Porous PEEK technology was
designed for enhanced osseointegration
and this study provides additional evi-
dence of its clinical value.” — EH
Pain Study: Stop
Opioids to RELIEVE
Pain
R
esearchers studying 551 Veteran
Affairs (VA) patients on long-term
opioid therapy for chronic, non-cancer-
related pain found that halting such
treatment does not make this type of
“It is notable that all patients who had
revision surgery with Cohere achieved
Cohere interbody fusion / Courtesy of NuVasive, Inc.
Wikimedia Commons and lincolnwood620
ryortho.com | 1-888-352-1952